Carlyle Leads USD123m Series D for Chinese Biotech Abbisko

The Carlyle Group led a USD123m Series D for China-based biotech firm Abbisko, with participation from Warburg Pincus, OrbiMed, and Lake Bleu Capital. Janchor Partners, Sage Partners, SHC, and Greater Bay Area Homeland Development Fund also participated in the round, and existing investors Lilly Asia Ventures, Temasek Holdings,… Read More

Sequoia China Leads USD150m Series B for Chinese Biotech Visen Pharmaceuticals

Sequoia Capital China led a USD150m Series B for China-based biotech firm Visen Pharmaceuticals, with participation from OrbiMed, Sherpa Healthcare Partners, Cormorant, HBM Healthcare Investments, Pivotal bioVenture Partners China, Logos Capital, and CDG Capital, as well as follow-on from existing investors, including Ascendis Pharma A/S, Vivo Capital, and… Read More



(default archive template)